This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.
Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. The product pipeline includes:
PV-10 For Metastatic Melanoma A Phase 2 clinical trial has been successfully completed, and preparations are underway for a Phase 3 randomized controlled study suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated. PV-10 has received Orphan Drug Designation from the US FDA for the treatment of melanoma. PV-10 For Metastatic Liver Cancer A Phase 1 clinical trial is currently underway.PV-10 has received Orphan Drug Designation from the US FDA for the treatment of liver cancer. PV-10 For Recurrent Breast Cancer A Phase 1 clinical trial has been successfully completed.A Compassionate Use Program for PV-10 is being conducted as an expanded access study.
Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.
PH-10 For Psoriasis A Phase 2 clinical trial has been successfully completed.A Phase 2c randomized clinical trial is currently underway. PH-10 For Atopic Dermatitis A Phase 2 clinical trial has been successfully completed.
Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.
Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.
For further information, read detailed Research Reports
------------------------------------------------------------------------------------------------------------------------------------------------------
Provectus Pharmaceuticals Launches Free Mobile Investor Relations ApplicationThursday January 24, 2013KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, pvct.com, a development-stage oncology and dermatology biopharmaceutical company, has launched a free mobile shareholder investor relations application.
The "Provectus IR" App is available for download from the App Store at www.itunes.com/appstore and from the Google Play Store at play.google.com. The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet.
-------------------------------------------------------------------------------------------------------------------------------------------------------
Provectus Web Presentation: HIGHLY RECOMMENDED VIEWING
"Opening a new front in the war against Cancer"
pvct.com
VIDEO AND AUDIO:
*PV-10 link to video and visual references:
http://www.pvct.com/multimedianews.html
PV-10 Trial Participants Telling Their Own Stories in the News
http://www.pvct.com/pv10-videos.html
May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.
http://www.pvct.com/hersey_pv10_video.html?pg=2
This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.
http://www.pvct.com/hersey_pv10_video.html?pg=5
2008, Charles Dawson, PV10 patient, Australia; Professor John Thompson, Sydney Melanoma Unit
Video can be viewed here
https://www.youtube.com/watch?v=HSjoev_q9Nw
December 16, 2010
Madja Rauh recently traveled to Bethlehem with her daughter Ursa Rauh from Ljubljana, the capital of Slovenia in Europe, to receive a promising, experimental treatment for metastatic melanoma with internationally recognized melanoma investigator Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology, St. Luke's Hospital & Health Network,Bethlehem, PA
Video can be viewed here.
http://www.slhn.org/News/2010/Slovenian-Woman-Receives-Treatment
http://www.pvct.com/inthenews.html?article=20110725&mode=0
Madja Rauh, PV10 patient, has a Facebook page as of 1/ 2015
http://www.pvct.com/inthenews.html?article=20070321&mode=0
http://www.pvct.com/inthenews.html?article=20110725&mode=0
Madja Rauh, PV-10 patient, has a Facebook page as of January 2015
May/June 2014
“Very Impressive Data” for Rose Bengal 10% in Intralesional Melanoma
Merrick Ross, chief of the melanoma section in the Department of Surgical Oncology at MD Anderson Cancer Center in Houston, says a phase 2 trial of Rose Bengal 10% as a chemical ablative agent injected directly into melanoma tumors yielded “very impressive data.” Even “bystander” lesions that were not injected showed good partial and complete responses, confirming the agent’s systemic value. Because of low toxicity, the treatment could be useful not only in combination with other therapies but as monotherapy for patients who aren’t good candidates for more toxic systemic treatments. American Society of Clinical Oncology, May/June 2014
Video can be viewed here.
http://www.ptcommunity.com/video/very-impressive-data-rose-bengal-10-intralesional-melanoma
--------------------------------------------------------------
PV-10 Audio References:
May 9, 2014 Dr. Sanjiv Agarwala Discusses PV-10 on Daybreak USA
On a recent airing of USA Radio National's Daybreak USA, host Jay Young interviewed Dr. Sanjiv S. Agarwala of St. Luke's Cancer Center in recognition of melanoma awareness month. Dr. Agarwala discusses melanoma risks and treatment as well as exciting results from his clinical work with treating advanced melanoma with PV-10.
With the permission of USA Radio National, an audio track containing the interview that aired on Daybreak USA is available at:
https://www.pvct.com/inthenews.html?article=20140509&mode=0
--------------------------------------------------------------
PVCT insiders transactions:
secform4.com
--------------------------------------------------------------
Contact Info
Our Contact Form
Telephone: +1 (866) 594-5999
Fax: +1 (866) 998-0005
info@pvct.com
Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA • MAP
Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Broadridge Corporate Issuer Solutions, Inc.
Laura Skorny
1717 Arch Street, Suite 1300
Philadelphia, PA 19103
E-mail: Laura.Skorny@Broadridge.com
Telephone: +1 (610) 649-7300
Fax: +1 (610) 649-7302
Investor Relations:
Porter, LeVay & Rose, Inc.
Marlon A. Nurse
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
Fax: 212-244-3075
marlon@plrinvest.com
Media Relations:
Porter, LeVay & Rose, Inc.
Bill Gordon
Seven Penn Plaza
New York, NY 10001
Telephone: 212-564-4700
bill@plrinvest.com
Investment Advisor:
Network 1 Financial Securities
Damon Testaverde
Telephone: +1 (800) 205-8031
--------------------------------------------------------------
Company Website
pvct.com
============================================================== |
